Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET

Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a conference call for April 12, 2022, at 8:00 a.m. ET to discuss its full-year 2021 earnings. The session will be accessible via teleconference or webcast, including audio and presenter-controlled slides. The company focuses on developing therapeutics addressing unmet medical needs across various platforms, including RNA therapeutics and nasal sprays. The replay of the call will be available for two weeks following the initial event.

Positive

• Focused on unmet medical needs with diverse product pipeline.
• Active in several therapeutic areas including RNA therapeutics and nasal sprays.

Negative

• None.

HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold an investor call on Tuesday, April 12, 2022, 8:00 a.m. ET to discuss its full-year 2021 earnings. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.

• Date: Wednesday, April 12, 2022 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)
• Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/45151
• Toll-free dial-in number: 877-545-0320
• International dial-in number: 973-528-0002
• Participant Access Code: 786152

Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.

Conference Call Replay

A replay of the call will be available after the live event and archived for two weeks until Tuesday, April 26, 2022.

• Toll-free dial-in number: 877-481-4010
• International dial-in number: 919-882-2331
• Replay Passcode: 45151

About Altamira Therapeutics

Altamira Therapeutics develops therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for the intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO".

Contact
Investors@altamiratherapeutics.com
800-460-0183

SOURCE: Altamira Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/695789/Altamira-Therapeutics-Sets-Full-Year-2021-Earnings-Call-for-Tuesday-April-12-2022-800-am-ET

FAQ

When is Altamira Therapeutics' earnings call for the full year 2021?

The earnings call is scheduled for April 12, 2022, at 8:00 a.m. ET.

How can I access the Altamira Therapeutics earnings call?

The call can be accessed via teleconference dial-in numbers or through a webcast available online.

What is the stock symbol for Altamira Therapeutics?

The stock symbol for Altamira Therapeutics is CYTO.

What are the main therapeutic areas for Altamira Therapeutics?

Altamira Therapeutics is focused on RNA therapeutics, nasal spray treatments, and therapies for tinnitus.

Will there be a replay available for the earnings call?

Yes, a replay of the call will be available for two weeks after the live event.